Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Dec;166(6):1393-400.
doi: 10.1093/infdis/166.6.1393.

High-dose Mefloquine in the Treatment of Multidrug-Resistant Falciparum Malaria

Affiliations
Clinical Trial

High-dose Mefloquine in the Treatment of Multidrug-Resistant Falciparum Malaria

F O ter Kuile et al. J Infect Dis. .

Abstract

The therapeutic efficacy and toxicity of a high-dose (25 mg/kg) mefloquine regimen (M25) and the currently recommended regimen of 15 mg/kg (M15) were compared in 199 patients with acute falciparum malaria in an area with deteriorating multidrug resistance on the Thai-Burmese border. The clinical and parasitologic responses were significantly more rapid with M25. The incidence of treatment failures by day 7-9 was 7% for M15 and 1% for M25 (P = .03) and had increased to 40% and 9%, respectively, by day 28 (P < .0001). Overall failure rates were highest in children (P = .02). Parasite clearance times were a good predictor of the therapeutic response; all patients with parasitemia persisting > 5 days after treatment experienced subsequent recrudescence. Side effects were dose-related and included dizziness, anorexia, nausea, vomiting, and fatigue. Although vomiting < 1 h after treatment was more likely in young children, children overall tolerated mefloquine better than adults, and men better than women. The optimum treatment dose of mefloquine in this area is 25 mg/kg.

Similar articles

See all similar articles

Cited by 39 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback